Search results for "Monocytic"

showing 10 items of 57 documents

Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia.

2014

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell neoplasm characterized by overlapping myelodysplastic and myeloproliferative features. Diagnosis is based on persistent mo...

Cancer Researchmedicine.diagnostic_testChronic myelomonocytic leukemiaLeukemia Myelomonocytic ChronicTrisomyHematologyBiologyTrisomy 8medicine.diseaseClonal Hematopoietic Stem CellOncologyhemic and lymphatic diseasesmedicineCancer researchNeoplasmHumansDetection rateIn Situ Hybridization FluorescenceFluorescence in situ hybridizationChromosomes Human Pair 8Leukemialymphoma
researchProduct

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypometh…

2017

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

OncologyAdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticeducationAzacitidineChronic myelomonocytic leukemiaDecitabine03 medical and health sciences0302 clinical medicineMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesInternal medicinemedicineHumansLetter to the Editorhealth care economics and organizationsAgedHematologybusiness.industryMyelodysplastic syndromesTranslational biologyfood and beveragesLeukemia Myelomonocytic Chronic[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyDNA MethylationMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesSurvival Analysis3. Good healthResponse assessmentLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisMyelodysplastic SyndromesImmunologyAzacitidineFemalebusiness030215 immunologymedicine.drug
researchProduct

New aspects in the histological examination of polyethylene wear particles in failed total joint replacements.

2002

The most important long-term complication in total joint replacements is aseptic osteolysis. Wear particles such as polyethylene (PE) debris are considered to be one of the causes that play a central role. Several studies indicated that PE can be visualised in paraffin-embedded tissue sections not only by polarised light, but also after oil red staining. To determine whether oil red staining enables sensitive detection of PE, we examined staining of mechanically-produced PE particles by oil red. Furthermore, we studied oil red staining of paraffin-embedded tissue specimens of patients with failed uncemented and cemented total knee and hip prostheses. We applied double labelling of sections …

MalePathologymedicine.medical_specialtyHistologyOsteolysisLightJoint ProsthesisTotal Joint ReplacementsAntigens Differentiation MyelomonocyticStainArthroplasty03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigens CDMaterials TestingmedicineHumansColoring AgentsHistological examination030222 orthopedicsChemistryCell BiologyGeneral MedicineProstheses and ImplantsPolyethylenemedicine.diseaseImmunohistochemistry3. Good healthSurgeryStainingProsthesis FailureMicroscopy Electron030220 oncology & carcinogenesisImmunohistochemistryFemaleJointsAseptic processingPolyethylenesAzo CompoundsActa histochemica
researchProduct

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

2011

Abstract Hydroxyurea is the standard therapy of chronic myelomonocytic leukemia (CMML) presenting with advanced myeloproliferative and/or myelodysplastic features. Response to hypomethylating agents has been reported in heterogeneous series of CMML. We conducted a phase 2 trial of decitabine (DAC) in 39 patients with advanced CMML defined according to a previous trial. Median number of DAC cycles was 10 (range, 1-24). Overall response rate was 38% with 4 complete responses (10%), 8 marrow responses (21%), and 3 stable diseases with hematologic improvement (8%). Eighteen patients (46%) demonstrated stable disease without hematologic improvement, and 6 (15%) progressed to acute leukemia. With…

OncologyNeuroblastoma RAS viral oncogene homologMalemedicine.medical_specialtyAntimetabolites AntineoplasticImmunologyDecitabineChronic myelomonocytic leukemiamedicine.disease_causeDecitabineBiochemistryhemic and lymphatic diseasesInternal medicinemedicineHumansSurvival analysisAgedAged 80 and overAcute leukemiaHematologybusiness.industryGene Expression Regulation LeukemicLeukemia Myelomonocytic ChronicCell BiologyHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisLeukemiaImmunologyMutationAzacitidineFemaleKRASbusinessmedicine.drugBlood
researchProduct

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.

2009

Abstract Abstract 2898 Poster Board II-874 Introduction: Panobinostat (LBH589) is a potent pan-deacetylase inhibitor (DACi) targeting epigenetic and non-epigenetic oncogenic pathways. Panobinostat is currently under clinical investigation in a variety of solid tumors and hematologic malignancies. A Phase IA/II trial evaluating oral panobinostat in patients (pts) with advanced hematologic malignancies is currently ongoing, and encouraging clinical activity has been reported previously in pts with lymphoma, myeloma, or leukemia. Here, preliminary activity of oral panobinostat in pts with myelofibrosis (MF) is described. Patients and methods: Pts with advanced hematologic malignancies were tre…

Oncologymedicine.medical_specialtyCytopeniaChemotherapybusiness.industrymedicine.medical_treatmentImmunologyChronic myelomonocytic leukemiaCell BiologyHematologyHematopoietic stem cell transplantationNeutropeniamedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationchemistry.chemical_compoundchemistryInternal medicinePanobinostatmedicinebusinessBlood
researchProduct

Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath.

2001

The expression of cysteine proteinases cathepsins B and K and of the endogenous inhibitor of cysteine proteinases, cystatin C, was investigated in tissue specimens of patients with giant cell tumor of tendon sheath (GCTTS). Expression of both enzymes was examined by immunohistochemistry in tissue specimens of 14 patients with GCTTS. Applying double-labeling techniques, the coexpression of cathepsin B and its major endogenous inhibitor cystatin C was additionally studied. Cells expressing the respective proteins were further characterized with the macrophage markers HAM56 and anti-CD68 (clone PG-M1). Cathepsin B could be detected in numerous HAM56-positive mononuclear cells (MC), but only in…

AdultMaleCathepsin KAntigens Differentiation MyelomonocyticCathepsin ECell CountCathepsin FBiologyCysteine Proteinase InhibitorsGiant CellsCathepsin BPathology and Forensic MedicineCathepsin CCathepsin BImmunoenzyme TechniquesTendonsCathepsin OCathepsin HAntigens CDCathepsin L1HumansCystatin CCathepsin SAgedMuscle NeoplasmsGiant Cell TumorsAntibodies MonoclonalMiddle AgedMolecular biologyCathepsinsCystatinsBiochemistryLeukocytes MononuclearFemaleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

Juvenile Xanthogranuloma and Nevus Anemicus in the Diagnosis of Neurofibromatosis Type 1

2013

Importance The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical criteria. However, they are of limited value before the age of 2 years. Juvenile xanthogranuloma (JXG) and nevus anemicus (NA) are commonly observed in children with NF1 and may be useful diagnostic clues. Objectives To evaluate the frequency of JXG and NA, to describe their clinical features, and to determine their diagnostic value in patients with NF1. Design, Setting, and Participants Retrospective medical record review of outpatients seen between January 1, 2005, and December 31, 2011. University hospital dermatology department affiliated with the French NF1 referral center network. Patients with NF1 diagn…

AdultMalePediatricsmedicine.medical_specialtyNeurofibromatosis 1Skin NeoplasmsAdolescentJuvenile xanthogranulomaChronic myelomonocytic leukemiaDermatologyHospitals UniversityYoung AdultmedicineHumansSex organYoung adultNeurofibromatosisChildNevusNevus anemicusAgedRetrospective Studiesbusiness.industryMedical recordAge FactorsInfant NewbornInfantRetrospective cohort studyMiddle Agedmedicine.diseaseEarly DiagnosisChild PreschoolFemaleFrancebusinessJAMA Dermatology
researchProduct

Janus -faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection

2012

We have generated unique asymmetric liposomes with phosphatidylserine (PS) distributed at the outer membrane surface to resemble apoptotic bodies and phosphatidic acid (PA) at the inner layer as a strategy to enhance innate antimycobacterial activity in phagocytes while limiting the inflammatory response. Results show that these apoptotic body-like liposomes carrying PA (ABL/PA) ( i ) are more efficiently internalized by human macrophages than by nonprofessional phagocytes, ( ii ) induce cytosolic Ca 2+ influx, ( iii ) promote Ca 2+ -dependent maturation of phagolysosomes containing Mycobacterium tuberculosis (MTB), ( iv ) induce Ca 2+ -dependent reactive oxygen species (ROS) production, (…

MaleAntitubercular AgentsApoptosisSettore MED/07Mice0302 clinical medicineInnateInbred BALB CMycobacterium tuberculosis liposomes0303 health sciencesMice Inbred BALB CMultidisciplinaryLeukemiaTumorbiologyMacrophages; Leukemia Monocytic Acute; Animals; Apoptosis; Calcium; Humans; Disease Models Animal; Mice; Cell Line Tumor; Immunity Innate; Reactive Oxygen Species; Mice Inbred BALB C; Liposomes; Phosphatidylserines; Tuberculosis Pulmonary; Adult; Bronchoalveolar Lavage Fluid; Middle Aged; Antitubercular Agents; Phagocytosis; Male; Mycobacterium tuberculosis; IsoniazidInterleukinPulmonaryMiddle AgedSettore BIO/193. Good healthPNAS PlusLeukemia Monocytic AcuteTumor necrosis factor alphaBronchoalveolar Lavage FluidIntracellularAdultPhagocytosisPhosphatidylserinesAcutePhagolysosomeSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAMicrobiologyCell LineMycobacterium tuberculosis03 medical and health sciencesPhagocytosisCell Line TumorIsoniazidTuberculosisAnimalsHumansTuberculosis Pulmonary030304 developmental biologySettore MED/04 - Patologia GeneraletherapyInnate immune systemMonocyticAnimalMacrophagesImmunityMycobacterium tuberculosisbiology.organism_classificationImmunity InnateDisease Models AnimalApoptosisImmunologyDisease ModelsLiposomesCalciumReactive Oxygen Species030215 immunology
researchProduct

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, m…

2016

BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to De…

OncologyMaleDenmarkProgrammed Cell Death 1 ReceptorCohort Studies0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineTreatment FailureReed-Sternberg CellsHazard ratioHematologyHodgkin DiseaseVinblastineDacarbazineSTAT1 Transcription FactorItalylymphoma PET Hodgkin030220 oncology & carcinogenesisDisease ProgressionbiomarkerFemalemedicine.drugAdultmedicine.medical_specialtyDacarbazineAntigens Differentiation MyelomonocyticSettore MED/08 - Anatomia PatologicaVinblastineDisease-Free Survival03 medical and health sciencesBleomycinAntigens CDInternal medicineHumansRetrospective StudiesFluorodeoxyglucosebusiness.industryRetrospective cohort studyPET scanmedicine.diseaseLymphomaSurgeryABVDReed–Sternberg cellDoxorubicinPositron-Emission TomographyMultivariate Analysisclassical Hodgkin's lymphoma:PolandbusinessBiomarkers030215 immunology
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct